Clinical trials
Phase 4 Cerebral Hemorrhage trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2018 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 5 |
| Unknown status | 4 |
| Completed | 2 |
| Not yet recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beijing Tiantan Hospital | 2 |
| Aarhus University Hospital | 1 |
| Cardinal Stefan Wyszynski University | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |
| Northwestern University | 1 |
| OSF Healthcare System | 1 |
| Oslo University Hospital | 1 |
| Qinhuangdao Hospital of Traditional Chinese Medicine | 1 |
| Region Skane | 1 |
| Rigshospitalet, Denmark | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cerebral Hemorrhage | 14 |
| Atrial Fibrillation | 3 |
| Ischemic Stroke | 3 |
| Intracranial Hemorrhages | 2 |
| Stroke | 2 |
| Subarachnoid Hemorrhage | 2 |
| Brain Edema | 1 |
| Brain Injuries, Traumatic | 1 |
| Cerebrovascular Disorders | 1 |
| Cognitive Dysfunction | 1 |
Trials
Showing 51 to 14 of 14. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.